ROCEPHIN IM 250 mg

Land: Jordanien

Sprache: Englisch

Quelle: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Wirkstoff:

Ceftriaxone 250 mg

Verfügbar ab:

مستودع ادوية شاوي و رشيدات و مسنات - Shawi & Rushedat Drug Store

ATC-Code:

J01DD04

INN (Internationale Bezeichnung):

Ceftriaxone 250 mg

Dosierung:

250 mg

Einheiten im Paket:

1+2ml SOLV.

Hergestellt von:

F.Hoffmann La- Roche (سويسرا)

Produktbesonderheiten:

6.92 :سعر الجمهور + الضريبة

Gebrauchsinformation

February 2022
Product Information GCC
Rocephin
_ _
February 2022
Product Information GCC
1
ROCEPHIN
®
Ceftriaxone
COMPOSITION
_Active ingredient:_
ceftriaxone (as the disodium salt).
Rocephin contains approximately 83 mg (3.6 mEq) of sodium per gram of
ceftriaxone.
PHARMACEUTICAL FORM AND ACTIVE SUBSTANCE QUANTITY PER UNIT
_250 mg i.v. _
_Dry substance:_
ceftriaxone 250 mg as disodium ceftriaxone per vial.
_Solvent:_
water for injection 5 ml.
_250 mg i.m. _
_Dry substance:_
ceftriaxone 250 mg as disodium ceftriaxone per vial.
_Solvent:_
lidocaine hydrochloride 20 mg, water q.s. 2 ml of solution.
_500 mg i.v. _
_Dry substance:_
ceftriaxone 500 mg as disodium ceftriaxone per vial.
_Solvent:_
water for injection 5 ml.
_500 mg i.m. _
_Dry substance:_
ceftriaxone 500 mg as disodium ceftriaxone per vial.
_Solvent:_
lidocaine hydrochloride 20 mg, water q.s. 2 ml of solution.
_1 g i.v. _
_Dry substance:_
ceftriaxone 1 g as disodium ceftriaxone per vial.
_Solvent:_
water for injection 10 ml.
_1 g i.m. _
_Dry substance:_
ceftriaxone 1 g as disodium ceftriaxone per vial.
_Solvent:_
lidocaine hydrochloride 35 mg, water q.s. 3.5 ml of solution.
_2 g i.v. _
_Dry substance:_
ceftriaxone 2 g as disodium ceftriaxone per vial.
INDICATIONS/USES
Infections caused by pathogens sensitive to ceftriaxone, e.g.:
-
respiratory tract infections, particularly pneumonia, and ear, nose
and throat infections;
-
abdominal infections (peritonitis, infections of the biliary and
gastrointestinal tracts);
-
renal and urinary tract infections;
-
genital infections, including gonorrhoea;
-
sepsis;
February 2022
Product Information GCC
Rocephin
_ _
February 2022
Product Information GCC
2
-
infections of the bones, joints, soft tissue, skin and of wounds;
-
infections in patients with impaired immunity;
-
meningitis;
-
disseminated Lyme borreliosis (stages II and III).
Perioperative prophylaxis of infections associated with
gastrointestinal, biliary , urogenital,
gynaecological surgery, but only in cases of potential or definite
contamination.
Officia